R&D
CENTER

Having embraced a strong and empowering R&D culture since its inception, Abdi İbrahim operates with high-tech infrastructure at its state-of-the-art formulation and analytical method development laboratories.

The Abdi İbrahim R&D Center has the capability and infrastructure to develop pharmaceuticals through inhalation technology and nanotechnology to meet the ever-changing and progressive needs of the national and international pharma industries.

The R&D Center focuses on developing added value and innovative products, achieving high success rate in bioequivalence studies, accelerating the process for bioequivalent product development and preparing Common Technical Document (CTD) files for Türkiye, Europe and other markets.

In addition to in-house projects, Abdi İbrahim also performs joint projects with local and foreign scientific institutions and universities that result in know-how and technology transfers.

Abdi İbrahim attaches particular importance to training and trained human resource, therefore, the Company’s cooperation with four different universities as part of the TÜBİTAK-2244 program plays a pivotal role in this regard. As part of the "Industrial PhD Program", we will grant scholarships to 12 PhD students in collaboration with TÜBİTAK and employ them in our R&D Center after they complete their PhD. 

As part of the TÜBİTAK-TEYDEP programs, we have continued to develop projects focusing on value-added generics and/or generics that we aim to roll out for the first time in Türkiye and around the world. Once the drugs developed within the project start to be used in patients, Türkiye will be less import-dependent on those drugs and this, in turn, will contribute to Türkiye 's economy through the export potential of said drugs.

We work closely with universities both independently and as part of the TÜBİTAK-ARDEB programs. Within the scope of our ongoing projects, we cooperate with more than one university for a single project through consortiums. All the projects where we cooperate with universities focus on developing value-added drugs that are produced using known molecules and that have never been used in patients anywhere around the world. Carrying out the clinical trials of the products, which are the deliverables of our university-industry cooperation, in collaboration with TÜSEB is another high-value-added R&D activity we have on our program pipeline.